Now people suffering from metastatic non-small cell lung cancer can live longer, without further deterioration of disease with the help of a tablet. Yes, Tarceva tablets have been approved by the U. S. Food and Drug Administration, or FDA, to be used as early treatment for such people.

It took three years to Roche to reach at a decision in which they would be publicizing a data of 74 clinical trials with regard to oseltamivir (Tamiflu). For past three years, debate has been going to reveal the data about all the clinical trials carried out for Tamiflu.

Reports from Roche had confirmed that the European Medicines Agency (EMA) has approved the drug Pegasys Plus ribavirin which is used for treating Hepatitis C virus (HCV) in children those who are five years of age or over.

Swiss lab Hoffmann-La Roche has developed an anti-inflammatory treatment, which is capable of reducing damage to heart muscles at the time of open heart surgery. The treatment inclacumab is said to be quite effective in reducing the molecular markers known as troponin I and CK-MB.

A recent report has uncovered that Roche and Chiasma would now be working together to develop Octreolin as well as to commercialize the same.

Perjeta has got an approval from the European Union to be used against cancer in combination with Herceptin and docetexal.

Though vemurafenib or Zelboraf, the brand name under which Roche sold it, was rejected by the National Institute for Health and Clinical Excellence (Nice) earlier, a recent report has revealed that the drug watchdog has approved the drug for use in the NHS.

As per reports, it has been revealed that Roche Holding AG, a Swiss drugmaker, was of the view they do not think they face any threat in coming time in regard to biosimilar copies of its quite famous cancer drug Rituxan.

Though a lot many pharmaceutical companies across the globe have been making cuts to reduce costs, Roche Holding AG has cleared that it is not going to become part of flocking. The pharmaceutical industry has been facing stiff competition from companies, which have been producing cost effective generics.

Restrictions to be put on two medicines are being urged by the European Medicines Agency (EMA), which concerns the drugs can cause more harms than the benefits these provide, as per a report uncovered recently.

It has been found that the medications containing tolperisone and trimetazidine are being asked to be replaced or simply removed.